Takeshi Arashiro
Overview
Explore the profile of Takeshi Arashiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Arashiro T, Miwa M, Nakagawa H, Takamatsu J, Oba K, Fujimi S, et al.
Vaccine
. 2023 Dec;
42(3):677-688.
PMID: 38114409
Introduction: Since the SARS-CoV-2 Omicron variant became dominant, assessing COVID-19 vaccine effectiveness (VE) against severe disease using hospitalization as an outcome became more challenging due to incidental infections via admission...
12.
Kasamatsu A, Otsuka M, Takahashi T, Arima Y, Arashiro T, Ito H, et al.
Sex Transm Infect
. 2023 Nov;
100(1):55-56.
PMID: 37977654
No abstract available.
13.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, et al.
Vaccine
. 2023 Oct;
41(47):6969-6979.
PMID: 37839947
Background: Repeated emergence of variants with immune escape capacity and waning immunity from vaccination are major concerns for COVID-19. We examined whether the surge in Omicron subvariant BA.5 cases was...
14.
Kinoshita R, Arashiro T, Kitamura N, Arai S, Takahashi K, Suzuki T, et al.
Emerg Infect Dis
. 2023 Jul;
29(9):1868-1871.
PMID: 37506681
A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%-29.6%). Seroprevalence studies...
15.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, et al.
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad240.
PMID: 37351451
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was...
16.
Kasamatsu A, Kanou K, Fukusumi M, Arima Y, Omori S, Nakamura H, et al.
J Epidemiol
. 2023 Jun;
34(4):187-194.
PMID: 37331795
Background: Little is known about the trends of imported infectious diseases among travelers to non-endemic countries during the novel coronavirus disease 2019 (COVID-19) pandemic. This article aimed to describe those...
17.
Kasamatsu A, Takahashi T, Arima Y, Otsuka M, Arashiro T, Ito H, et al.
Sex Health
. 2023 Jun;
20(4):370-372.
PMID: 37282345
Based on national surveillance data, we describe an unprecedented increase in syphilis case reports in Japan, with a surge in 2021-2022 reaching 10141 cases in Week 42, 2022, a 1.7-fold...
18.
Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, et al.
iScience
. 2023 May;
26(5):106694.
PMID: 37124417
Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with...
19.
Shimbashi R, Shiino T, Ainai A, Moriyama S, Arai S, Morino S, et al.
Glob Health Med
. 2023 Mar;
5(1):5-14.
PMID: 36865900
As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers....
20.
Arashiro T, Arai S, Kinoshita R, Otani K, Miyamoto S, Yoneoka D, et al.
Influenza Other Respir Viruses
. 2023 Feb;
17(2):e13094.
PMID: 36824391
Background: Based on routine surveillance data, Japan has been affected much less by COVID-19 compared with other countries. To validate this, we aimed to estimate SARS-CoV-2 seroprevalence and examine sociodemographic...